Cogent Biosciences Inc

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

COGT$31.64-5.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Series A Non-Voting Convertible · Series B Non-Voting Convertible · Additional · Accumulated · Total
Preferred Stock · Preferred Stock · Common Stock · Paid-in · Other Comprehensive · Accumulated · Stockholders’
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	(Income) Loss	Deficit	Equity
Balances at December 31, 2021	103,289	$85,400	—	$—	43,805,922	$44	$399,713	$—	$(270,973)	$214,184
Issuance of common stock in underwritten public offering, net of offering costs of $10.8 million	—	—	—	—	17,899,698	18	161,897	—	—	161,915
Pre-funded warrant exercise	—	—	—	—	2,424,242	2	22	—	—	24
Conversion of Series A non-voting convertible preferred stock into common stock	(22,239)	(19,570)	—	—	5,559,750	6	19,564	—	—	—
Issuance of common stock under Employee Stock Purchase Plan	—	—	—	—	49,000	—	351	—	—	351
Issuance of common stock from exercises	—	—	—	—	154,822	—	1,238	—	—	1,238
Unrealized losses on marketable securities	—	—	—	—	—	—	—	(104)	—	(104)
Stock-based compensation expense	—	—	—	—	—	—	18,368	—	—	18,368
Net loss	—	—	—	—	—	—	—	—	(140,241)	(140,241)
Balances at December 31, 2022	81,050	$65,830	—	$—	69,893,434	$70	$601,153	$(104)	$(411,214)	$255,735
Issuance of common stock in underwritten public offering, net of offering costs of $10.7 million	—	—	—	—	14,375,000	14	161,775	—	—	161,789
Conversion of Series A non-voting convertible preferred stock into common stock	(6,585)	(5,795)	—	—	1,646,250	2	5,793	—	—	—
Issuance of common stock under Employee Stock Purchase Plan	—	—	—	—	85,878	—	752	—	—	752
Issuance of common stock from exercises	—	—	—	—	123,687	—	965	—	—	965
Unrealized gains on marketable securities	—	—	—	—	—	—	—	350	—	350
Stock-based compensation expense	—	—	—	—	—	—	30,621	—	—	30,621
Net loss	—	—	—	—	—	—	—	—	(192,410)	(192,410)
Balances at December 31, 2023	74,465	$60,035	—	$—	86,124,249	$86	$801,059	$246	$(603,624)	$257,802
Issuance of Series B non-voting convertible preferred stock and common stock, net of issuance costs of $11.7 million, in connection with the Private Placement	—	—	12,280	87,311	17,717,997	18	125,958	—	—	213,287
Exchange of common stock for Series B non-voting convertible preferred stock	—	—	8,300	74,754	(8,300,000)	(8)	(74,746)	—	—	—
Conversion of Series B non-voting convertible preferred stock into common stock	—	—	(13,712)	(107,980)	13,712,000	13	107,967	—	—	—
Conversion of Series A non-voting convertible preferred stock into common stock	(4,000)	(3,520)	—	—	1,000,000	1	3,519	—	—	—

Issuance of common stock under Employee Stock Purchase Plan	—	—	—	—	176,893	—	916	—	—	916
Issuance of common stock from exercises	—	—	—	—	30,590	—	199	—	—	199
Unrealized gains on marketable securities	—	—	—	—	—	—	—	201	—	201
Stock-based compensation expense	—	—	—	—	—	—	39,740	—	—	39,740
Net loss	—	—	—	—	—	—	—	—	(255,859)	(255,859)
Balances at December 31, 2024	70,465	$56,515	6,868	$54,085	110,461,729	$110	$1,004,612	$447	$(859,483)	$256,286

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.